Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EFFORT: Empagliflozin and Finerenone Combination in Obesity with Hypertension
NCT07678151Not yet recruiting
- Sponsor
- Heart Health Research Center
- Start
- Jul 2026
- Primary completion
- Apr 2027
- Countries
- 1
01
Overview
Randomised, double-blind trial of empagliflozin and finerenone in hypertension (HTN) (2 arms), sponsored by Heart Health Research Center. Primary endpoint: Change in Unattended Office Systolic Blood Pressure at 12 weeks. Planned start Jul 2026; status: not yet recruiting.
02
Drugs
empagliflozinfinerenone
03
Conditions
hypertension (HTN)
Beyond the preview
Go deeper on NCT07678151.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07678151.